NASDAQ:XFOR
X4 Pharmaceuticals Inc. Stock News
$1.15
+0.0700 (+6.48%)
At Close: May 03, 2024
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024
08:00am, Tuesday, 30'th Apr 2024
BOSTON, April 30, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it wil
US FDA approves X4 Pharmaceuticals' drug for immunodeficiency disease
06:37am, Monday, 29'th Apr 2024
The U.S. FDA has approved X4 Pharmaceuticals' drug to treat a rare genetic immunodeficiency disease, the company said on Monday.
X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences
08:00am, Monday, 01'st Apr 2024
BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management w
BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it wil
X4: Dip Following Mixed Results In Chronic Neutropenia Indication Worth Buying
11:43pm, Wednesday, 13'th Dec 2023
X4 Pharmaceuticals has dipped considerably following updated results presented in ASH suggesting that mavorixafor may not be effective as monotherapy in chronic neutropenia (excluding WHIM). Mavorixaf
X4 Pharmaceuticals to Participate in Upcoming November Investor Conferences
08:00am, Friday, 10'th Nov 2023
BOSTON, Nov. 10, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management wi
X4 Pharmaceuticals, Inc. (XFOR) Q3 2023 Earnings Call Transcript
12:37pm, Thursday, 09'th Nov 2023
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Dan Ferry – LifeSci Advisors Paula Ragan – Chief Executive Officer Mark Ba
X4 Pharmaceuticals to Report Third-Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 9, 2023
08:00am, Thursday, 02'nd Nov 2023
BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will
X4 Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
08:00am, Tuesday, 19'th Sep 2023
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management w
X4 Pharmaceuticals to Report Second-Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 10, 2023
08:01am, Wednesday, 02'nd Aug 2023
BOSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of
X4 Pharmaceuticals, Inc. (XFOR) Q1 2023 Earnings Call Transcript
07:35pm, Saturday, 06'th May 2023
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Dr. Paula Ragan - President and CEO Adam Mostafa -
X4 Pharmaceuticals to Report First-Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 4, 2023
08:01am, Wednesday, 26'th Apr 2023
BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of
X4 Pharmaceuticals shares lift as investors await new data from WHIM syndrome study
10:58am, Wednesday, 12'th Apr 2023
X4 Pharmaceuticals, the Boston-based drug developer, saw its stock trading higher on Wednesday as investors gear up for new results from a Phase 3 trial of its oral cxcr4 antagonist, mavorixafor, for
X4 Pharmaceuticals: Chronic Neutropenia Might Finally Have Met Its Match
04:29am, Wednesday, 12'th Apr 2023
Positive P3 results of mavorixafor for first-ever treatment of WHIM syndrome with possible BLA approval in 1H 2024. A large chronic neutropenia market could see their first approved drug in over 30 ye
BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases o
